Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COCH NASDAQ:CODX NASDAQ:POCI NASDAQ:PYPD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOCHEnvoy Medical$1.46-1.4%$1.50$1.21▼$3.99$31.85M2.2117,016 shs4,555 shsCODXCo-Diagnostics$0.27+0.9%$0.27$0.23▼$2.23$8.83M0.51839,846 shs1.10 million shsPOCIPrecision Optics$4.73+1.7%$4.75$3.47▼$6.59$35.65M0.35,659 shs1,967 shsPYPDPolyPid$3.43-1.7%$3.49$2.30▼$3.93$55.48M1.487,166 shs37,480 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOCHEnvoy Medical-1.35%-0.68%-10.98%-13.10%-47.10%CODXCo-Diagnostics+2.08%+7.58%-0.64%-11.53%-78.07%POCIPrecision Optics+1.72%+2.60%-5.89%+4.65%-11.59%PYPDPolyPid-1.72%+6.85%-2.00%+25.18%-1.72%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOCHEnvoy Medical3.4578 of 5 stars3.55.00.00.02.73.30.0CODXCo-Diagnostics4.5803 of 5 stars3.55.00.04.43.30.01.3POCIPrecision Optics0.7446 of 5 stars0.03.00.00.03.80.80.0PYPDPolyPid3.0198 of 5 stars3.65.00.00.02.41.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOCHEnvoy Medical 3.00Buy$9.25533.56% UpsideCODXCo-Diagnostics 3.00Buy$5.501,972.34% UpsidePOCIPrecision Optics 0.00N/AN/AN/APYPDPolyPid 3.17Buy$12.40261.52% UpsideCurrent Analyst Ratings BreakdownLatest CODX, PYPD, POCI, and COCH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/14/2025PYPDPolyPidCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $13.008/14/2025PYPDPolyPidRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy8/13/2025PYPDPolyPidHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.006/18/2025PYPDPolyPidRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$12.00 ➝ $9.006/17/2025PYPDPolyPidJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$16.00 ➝ $14.006/9/2025PYPDPolyPidHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$11.00 ➝ $13.006/5/2025PYPDPolyPidRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$9.006/2/2025PYPDPolyPidHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$11.005/27/2025COCHEnvoy MedicalAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.25 ➝ $9.50(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOCHEnvoy Medical$220K142.81N/AN/A($1.39) per share-1.05CODXCo-Diagnostics$3.91M2.28N/AN/A$1.70 per share0.16POCIPrecision Optics$19.10M1.90N/AN/A$1.66 per share2.85PYPDPolyPidN/AN/AN/AN/A$0.75 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOCHEnvoy Medical-$20.80M-$1.43N/AN/AN/A-10,961.26%N/A-236.14%N/ACODXCo-Diagnostics-$37.64M-$1.17N/AN/AN/A-1,025.45%-60.16%-52.69%N/APOCIPrecision Optics-$2.95M-$0.89N/A∞N/A-32.84%-54.03%-32.48%9/29/2025 (Estimated)PYPDPolyPid-$29.02M-$4.30N/A∞N/AN/A-1,042.66%-167.87%N/ALatest CODX, PYPD, POCI, and COCH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CODXCo-Diagnostics-$0.25-$0.23+$0.02-$0.23$0.30 million$0.16 million8/13/2025Q2 2025PYPDPolyPid-$0.53-$0.78-$0.25-$0.78N/AN/A7/31/2025Q2 2025COCHEnvoy Medical-$0.29-$0.32-$0.03-$0.32$0.07 million$0.08 million5/15/2025Q3 2025POCIPrecision OpticsN/A-$0.30N/A-$0.30N/A$4.19 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOCHEnvoy MedicalN/AN/AN/AN/AN/ACODXCo-DiagnosticsN/AN/AN/AN/AN/APOCIPrecision OpticsN/AN/AN/AN/AN/APYPDPolyPidN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOCHEnvoy MedicalN/A0.940.74CODXCo-DiagnosticsN/A4.434.23POCIPrecision Optics0.111.991.26PYPDPolyPid4.430.710.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOCHEnvoy Medical8.59%CODXCo-Diagnostics14.99%POCIPrecision Optics13.71%PYPDPolyPid26.47%Insider OwnershipCompanyInsider OwnershipCOCHEnvoy Medical58.90%CODXCo-Diagnostics8.40%POCIPrecision Optics12.99%PYPDPolyPid24.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOCHEnvoy Medical3421.52 million8.85 millionNot OptionableCODXCo-Diagnostics10033.57 million30.75 millionOptionablePOCIPrecision Optics807.67 million6.67 millionNot OptionablePYPDPolyPid8015.90 million11.97 millionNo DataCODX, PYPD, POCI, and COCH HeadlinesRecent News About These CompaniesPolyPid's (PYPD) "Buy" Rating Reaffirmed at HC Wainwright25 minutes ago | americanbankingnews.comPolyPid price target raised to $10 from $9 at Roth CapitalAugust 14 at 6:21 PM | msn.comPolyPid Releases Mid-2025 Financial UpdateAugust 14 at 6:21 PM | theglobeandmail.comPolyPid Reports Strong Phase 3 Results and Financial UpdateAugust 14 at 10:27 AM | msn.comPolyPid Ltd. (NASDAQ:PYPD) Q2 2025 Earnings Call TranscriptAugust 14 at 10:27 AM | msn.comPolyPid Ltd (PYPD) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Rising ExpensesAugust 14 at 10:27 AM | finance.yahoo.comPolyPid Ltd. (PYPD) Q2 2025 Earnings Call TranscriptAugust 13 at 5:04 PM | seekingalpha.comPolyPid sees cash runway ‘well into’ 2026August 13 at 2:01 PM | msn.comPolyPid Reports Positive Phase 3 Results and Strengthens LeadershipAugust 13 at 8:17 AM | tipranks.comPolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial ResultsAugust 13 at 7:30 AM | globenewswire.comPolyPid Ltd.: PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical OfficerAugust 12 at 5:57 PM | finanznachrichten.dePolyPid appoints Tweezer-Zaks as Chief Medical OfficerAugust 12 at 5:57 PM | msn.comPolyPid Appoints New Chief Medical Officer Amid Strategic AdvancementsAugust 12 at 5:57 PM | msn.comPolyPid Ltd. Appoints Dr. Nurit Tweezer-Zaks as Chief Medical OfficerAugust 12 at 9:00 AM | quiverquant.comQPolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical OfficerAugust 12 at 8:00 AM | globenewswire.comPolyPid Ltd. (NASDAQ:PYPD) Given Average Rating of "Buy" by BrokeragesAugust 6, 2025 | americanbankingnews.comPolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025July 30, 2025 | globenewswire.comPYPD: Positive Topline Data From D-PLEX₁₀₀ Trial Contributes to Multiple Subsequent BenefitsJuly 16, 2025 | finance.yahoo.comPolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss MarketJuly 15, 2025 | finance.yahoo.comPolyPid Launches Long-Acting GLP-1 Delivery Platform for Diabetes MarketJuly 15, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCODX, PYPD, POCI, and COCH Company DescriptionsEnvoy Medical NASDAQ:COCH$1.46 -0.02 (-1.35%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$1.46 0.00 (0.00%) As of 08/14/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.Co-Diagnostics NASDAQ:CODX$0.27 +0.00 (+0.91%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$0.26 0.00 (-1.66%) As of 08/14/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.Precision Optics NASDAQ:POCI$4.71 +0.06 (+1.27%) As of 08/14/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Precision Optics Corporation, Inc. designs, develops, manufactures, and sells specialized optical and illumination systems and related components primarily in the United States and the European Economic Area. It offers medical instrumentation products, including endoscopes and endocouplers, as well as other custom imaging and illumination products, such as Microprecision lenses and micro medical cameras, and 3D endoscopes for use in minimally invasive surgical procedures by hospitals and physicians. The company also provides components and assemblies for industrial and military use. It markets its products to medical device companies. The company was incorporated in 1982 and is based in Gardner, Massachusetts.PolyPid NASDAQ:PYPD$3.43 -0.06 (-1.72%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$3.37 -0.06 (-1.78%) As of 08/14/2025 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Deere’s Sell-Off Could Be a Long-Term Buying Chance Cisco Systems: The Only AI Stock Income Investors Need to Own Gartner’s RSI Just Sank to 11: That’s a Setup You Can’t Ignore How Did Peter Thiel-Backed Crypto Exchange Bullish's IPO Go? Mercury Systems Up 27%: Financials Send Investors a Clear Signal Brinker Serves Up Earnings Beat, Sidesteps Cost Pressures CAVA’s Honeymoon Ends With a 16% Stock Drop Rigetti Stock: A Long-Term Quantum Play Facing Short-Term Tests Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access